These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19126808)

  • 41. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Controversies surrounding hormonal deprivation.
    Denis LJ
    Acta Urol Belg; 1996 May; 64(2):81-4. PubMed ID: 8701819
    [No Abstract]   [Full Text] [Related]  

  • 43. Monotherapy versus combined androgen blockade in patients with advanced prostate cancer.
    Errejon A; Crawford ED
    Cancer; 2002 Jul; 95(2):209-10. PubMed ID: 12124816
    [No Abstract]   [Full Text] [Related]  

  • 44. Global update on the use of hormonal therapy for the management of high-risk prostate cancer: introduction.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():1. PubMed ID: 17229158
    [No Abstract]   [Full Text] [Related]  

  • 45. Androgen suppression plus radiation for prostate cancer.
    Millar J
    JAMA; 2004 Dec; 292(21):2581-2; author reply 2582. PubMed ID: 15572714
    [No Abstract]   [Full Text] [Related]  

  • 46. Castration-resistant prostate cancer: adaptive responses in the androgen axis.
    Egan A; Dong Y; Zhang H; Qi Y; Balk SP; Sartor O
    Cancer Treat Rev; 2014 Apr; 40(3):426-33. PubMed ID: 24139549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
    Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
    J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review.
    Fakih M; Johnson CS; Trump DL
    Urology; 2002 Oct; 60(4):553-61. PubMed ID: 12385906
    [No Abstract]   [Full Text] [Related]  

  • 49. Role of radiation and androgen deprivation therapy for advanced prostate cancer.
    Jani AB; Rossi PJ
    Curr Probl Cancer; 2015; 39(1):41-7. PubMed ID: 25554467
    [No Abstract]   [Full Text] [Related]  

  • 50. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
    Pitts WR
    BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186
    [No Abstract]   [Full Text] [Related]  

  • 51. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
    Taplin ME; Bubley GJ; Ko YJ; Small EJ; Upton M; Rajeshkumar B; Balk SP
    Cancer Res; 1999 Jun; 59(11):2511-5. PubMed ID: 10363963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Arguments against long term use of complete androgenic blockers].
    Studer UE; Bitton A
    Prog Urol; 1997 Sep; 7(4):662-4. PubMed ID: 9410330
    [No Abstract]   [Full Text] [Related]  

  • 54. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer: the new standard?
    DeWeese TL
    JAMA; 2004 Aug; 292(7):864-6. PubMed ID: 15316002
    [No Abstract]   [Full Text] [Related]  

  • 56. New treatment for advanced prostate cancer.
    FDA Consum; 2004; 38(2):4. PubMed ID: 15101352
    [No Abstract]   [Full Text] [Related]  

  • 57. Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. Eur urol 2013;64:517-8.
    Cronauer MV; Schrader MG; Schrader AJ
    Eur Urol; 2014 Jan; 65(1):e10-1. PubMed ID: 23993161
    [No Abstract]   [Full Text] [Related]  

  • 58. Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. Eur Urol 2013;64:517-8.
    Canipari C; Caroti C; Boccardo F
    Eur Urol; 2014 Apr; 65(4):e54-5. PubMed ID: 24341956
    [No Abstract]   [Full Text] [Related]  

  • 59. Development of androgen resistance in prostatic cancer.
    Isaacs JT; Schulze H; Coffey DS
    Prog Clin Biol Res; 1987; 243A():21-31. PubMed ID: 3309971
    [No Abstract]   [Full Text] [Related]  

  • 60. [Hormonal treatment in cancer of the prostate].
    Boccon-Gibod L
    Rev Prat; 1987 Feb; 37(7):386-90. PubMed ID: 3823774
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.